Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 6/20 | 0.53 |
| ▸ | CASP5 | P51878 | 6/20 | 0.53 |
| ▸ | CASP4 | P49662 | 5/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1123752 | 0.82 | CASP1 (0.78) | CASP1CASP5CASP4KMT2AHTT | |
| SCHEMBL4327006 | 0.78 | MPO (0.75) | MPOKMT2AMAPTTSHR | |
| SCHEMBL1442813 | 0.77 | PIK3CB (0.50) | PIK3CAKMT2APIK3CBMAPTHTT | |
| SCHEMBL1444289 | 0.77 | PIK3CA (0.46) | PIK3CAKMT2APIK3CBMAPTGBA1 | |
| SCHEMBL10787841 | 0.77 | MPO (0.72) | MPOKMT2AMAPTTSHR | |
| SCHEMBL1124300 | 0.76 | HTT (0.62) | CASP1CASP5PIK3CAKMT2APIK3CB | |
| SCHEMBL1123979 | 0.76 | HTT (0.62) | CASP1CASP5PIK3CAKMT2APIK3CB | |
| SCHEMBL1123614 | 0.76 | HTT (0.62) | CASP1CASP5PIK3CAKMT2APIK3CB | |
| SCHEMBL3991347 | 0.76 | CASP1 (0.67) | CASP1CASP5CASP4KMT2AMAPT | |
| SCHEMBL9689529 | 0.75 | CASP1 (0.59) | CASP1CASP5CASP4KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2473486-B2 | PYRIMIDINES AS HEPCIDINE ANTAGONISTS | VIFOR INT AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| EP-2473486-B2 | PYRIMIDINES AS HEPCIDINE ANTAGONISTS | VIFOR INT AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| EP-2473486-B1 | PYRIMIDINES AS HEPCIDINE ANTAGONISTS | VIFOR INT AG (CH) | 2015-10-28 | — | — | EP | disclosed |
| EP-2473486-B1 | PYRIMIDINES AS HEPCIDINE ANTAGONISTS | VIFOR INT AG (CH) | 2015-10-28 | — | — | EP | disclosed |
| US-20120202806-A1 | Novel Pyrimidine- And Triazine-Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20120202806-A1 | Novel Pyrimidine- And Triazine-Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20120202806-A1 | Novel Pyrimidine- And Triazine-Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-09 | — | — | US | disclosed |
| WO-2011026835-A1 | NOVEL PYRIMIDINE AND TRIAZINE HEPCIDINE ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202806-A1 | Novel Pyrimidine- And Triazine-Hepcidine Antagonists | HAMP, DHPS, SLC40A1 | MPO 1729/4885CASP1 2392/4885CASP5 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.